Wells Fargo & Company MN trimmed its position in MacroGenics, Inc. (NASDAQ:MGNX) by 48.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,852 shares of the biopharmaceutical company’s stock after selling 23,348 shares during the period. Wells Fargo & Company MN owned about 0.07% of MacroGenics worth $435,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Jennison Associates LLC boosted its position in MacroGenics by 0.6% in the second quarter. Jennison Associates LLC now owns 189,970 shares of the biopharmaceutical company’s stock worth $3,326,000 after purchasing an additional 1,062 shares during the last quarter. American International Group Inc. boosted its position in MacroGenics by 7.1% in the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 1,300 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in MacroGenics by 21.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 148,792 shares of the biopharmaceutical company’s stock worth $2,606,000 after purchasing an additional 25,823 shares during the last quarter. Vanguard Group Inc. boosted its position in MacroGenics by 3.4% in the first quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock worth $25,163,000 after purchasing an additional 44,680 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in MacroGenics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 159,839 shares of the biopharmaceutical company’s stock worth $2,799,000 after purchasing an additional 25,279 shares during the last quarter. 84.72% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2017/11/14/wells-fargo-company-mn-reduces-holdings-in-macrogenics-inc-mgnx.html.

In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of MacroGenics stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares of the company’s stock, valued at approximately $800,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.

MacroGenics, Inc. (NASDAQ:MGNX) opened at $17.85 on Tuesday. MacroGenics, Inc. has a twelve month low of $14.36 and a twelve month high of $31.85.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $5.50 million. During the same period in the prior year, the firm posted ($0.97) earnings per share. The firm’s revenue for the quarter was down 48.5% on a year-over-year basis. analysts anticipate that MacroGenics, Inc. will post -2.34 EPS for the current fiscal year.

A number of research analysts have recently weighed in on the company. ValuEngine cut MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Citigroup Inc. lifted their price objective on MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research report on Friday. BidaskClub cut MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Morgan Stanley lowered their price objective on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. MacroGenics presently has a consensus rating of “Buy” and an average target price of $30.10.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.